Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. It develops several patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The company was founded on June 14, 2021 and is headquartered in Calgary, Canada.